SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-18-143415
Filing Date
2018-04-30
Accepted
2018-04-30 16:46:04
Documents
10
Period of Report
2018-06-26
Effectiveness Date
2018-04-30

Document Format Files

Seq Description Document Type Size
1 DEF 14A d473444ddef14a.htm DEF 14A 413035
2 GRAPHIC g473444g09j86.jpg GRAPHIC 21232
3 GRAPHIC g473444g30y95.jpg GRAPHIC 20437
4 GRAPHIC g473444g42c40.jpg GRAPHIC 30554
5 GRAPHIC g473444g81b73.jpg GRAPHIC 20851
6 GRAPHIC g473444g85w06.jpg GRAPHIC 28501
7 GRAPHIC g473444g92r65.jpg GRAPHIC 20197
8 GRAPHIC g473444g94t16.jpg GRAPHIC 19184
9 GRAPHIC g473444page08.jpg GRAPHIC 225812
10 GRAPHIC g473444page09.jpg GRAPHIC 199774
  Complete submission text file 0001193125-18-143415.txt   1223111
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37465 | Film No.: 18790606
SIC: 2834 Pharmaceutical Preparations